Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Recruiting

Phase 1

Phase 2

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

Sponsor:

Tango Therapeutics, Inc.

Code:

NCT05887492

Conditions

Non Small Cell Lung Cancer

Solid Tumors, Adult

Lung Cancer

Lung Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

TNG260

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-10. This information was provided to ClinicalTrials.gov by Tango Therapeutics, Inc. on 2025-04-11.